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Chronic kidney disease (CKD) is highly prevalent and a multiplier of cardiovascular disease (CVD) and cannot be completely
explained by traditional Framinghan risk factors. Consequently, greater emphasis has been placed in nontraditional risk factors,
suchas inﬂammation,endothelialdysfunction, sympathetic overactivation, protein-energy wastingoxidative stress,vascularcalci-
ﬁcation,andvolumeoverload. The accumulationofuremictoxins (andthe involvementofgenetic factors) isresponsible formany
of the clinical consequences of a condition known as uremia. In this brief paper, we discuss mechanisms involved in the vascular
damage of CKD patients, aiming to point out that important factors beyond hypertension are largely responsible for endothelial
activation and increased CVD risk, with potential impact on risk stratiﬁcation and development of novel therapeutic options.
1.Introduction
Chronic kidney disease (CKD) is a disease in exponential
growth,and, alongwithotherchronic diseases, is responsible
for 25 million deaths per year, mainly due to the multipli-
cation of cardiovascular disease (CVD) [1]. Cardiovascular
disease is independently associated with CKD, and this
cardiovascular risk cannot be completely explained by tradi-
tional Framinghan risk factors (age, lifestyle, left ventricular
hypertrophy, dyslipidemia, hypertension, and diabetes mel-
litus) [2]. Consequently, greater emphasis has been placed in
nontraditional risk factors, such as inﬂammation, endothe-
lial dysfunction, sympathetic overactivation, protein-energy
wasting oxidative stress, vascular calciﬁcation, and volume
overload [3,4].Inpatientswithstage5 CKD,CVDriskisﬁve
times greater than in the general population, evenafter strat-
iﬁcation for age, sex, race, and diabetes [5]. Hypertension is
verycommon inthis population,and itsprevalenceincreases
with progression of the disease. Moreover, with retention of
sodium, expansion of extracellular volume, and activation of
renin angiotensinsystem, allhighly prevalentinCKD,hyper-
tension becomes refractory to treatment and an universal
conditioninadvancedstagesofCKD.However,hypertension
alone, although important and highly prevalent, cannot by
itself justify the enormous cardiovascular burden in CKD.
In the progression of CKD, the kidneys lose their ability
to eﬀectivelyremovetoxiccompoundsfromthe bloodstream
for subsequent formation of urine, resulting in its accumula-
tion in the body. The accumulation of these uremic toxins
(and the involvement of genetic factors) is responsible for
many of the clinical consequences of a condition known
as uremia [6, 7]. Among the toxic eﬀects of uremia, the
most important due to its impact on clinical outcome is the
multiplication in cardiovascular risk. In this brief paper, we
discuss mechanisms involved in the vascular damage ofCKD
patients, aiming to point out that important factors beyond
hypertension are largely responsible for endothelial activa-
tion and increased CVD risk, with potential impact on risk
stratiﬁcation and development of novel therapeutic options.
2.Chronic KidneyDisease and Uremic Toxicity
Currently there are over 100 identiﬁed uremic compounds,
which are classiﬁed according to their physical and chemical
characteristics of removal by dialysis in: (i) small water-
solublecompounds(e.g.,ureaanduricacid),whichareeasily2 International Journal of Hypertension
removed by dialysis and not necessarily with a functional
toxicity;(ii)compoundsofmoderatemolecularweight (e.g.,
β2-microglobulin and leptin), only removed by special dial-
ysis strategies and that aﬀect many organ systems; (iii)
compounds bound to proteins, generally with low molecular
weight (e.g., phenols and indoles), diﬃcult to remove by
dialysis and capable to enhance many toxic activities in the
body [8–10]. Uremic toxins cannot be deﬁned simply as sub-
stances present in body ﬂuids of uremic patients. It should
also be shown as connection between the toxic substance
and one or more events, pathobiological or clinical [6].
Uremic toxicity aﬀects almost every organ system; therefore,
cardiovasculardamageis knowntohavethemajorimpacton
morbimortality of CKD patients [8].
3.EndothelialDysfunction andCKD
The endotheliumisconstitutedby a single layerofcellsat the
interior surface of blood vessels, and it is the largest organ
in the body and the main regulator of vascular homeostasis,
covering a surface area of approximately 4.000 to 7.000m2
[11]. Moreover, because of its enormous surface area, the
endothelium is involved in many disease conditions, but
mostly itis thevictim ofthe so-called cardiovascular risk fac-
tors, for example, hypertension and diabetes [12]. Endothe-
lial dysfunction is a commoneventdescribed inrenal failure,
both chronic and acute, as well as in all end-stage renal
diseases. Itisbelievedthat theaccumulationofuremic toxins
may lead to an endothelial inﬂammatory response [9, 13].
Indeed, exposure of endothelium to these toxins (a manifes-
tation of uremic toxicity) leads to changes in cellular phe-
notype and production of many proinﬂammatory molecules
[14, 15], with rapid degeneration of cardiovascular system.
In the progression and development of atherosclerosis,
some important toxins can be mentioned. First, the produc-
tion of reactive oxygen species (ROS) in endothelial cells,
which is stimulated by indoxyl sulfate, may contribute to the
inﬂammatory state found in CVD [16]. The interaction of
ROS with proteins can be responsible for the expression of
nitrotyrosine by endothelial cells and high-level expression
of receptors for advanced glycation end products (AGEs)
[17–19]. In the cardiovascular system, AGEs accumulation
contributes to stiﬀening of the arteries due to its binding to
collagen and elastin in a disorderly and not functional way
[20]. In addition, uremic toxicity leads to an impairment
in endothelium nitric oxide (NO) synthesis, which plays a
crucial role in vascular protection since NO inhibits pro-
liferation and migration of VSMC, expression of adhesion
molecules, and platelet aggregation [21].
Second, symmetric dimethylarginine (ADMA) is an im-
portant protein-bound, low-molecular-weight potential ure-
mic toxin and reported to be a novel risk factor for endothe-
lial dysfunction, strongly correlated with impaired ﬂow-
mediated vasodilation and with carotid intima-media thick-
ness [6, 22, 23]. Moreover, high oxidative stress, AGEs, and
ADMAdecrease theendogenousnitric oxidesynthase (eNO)
activity and cause impairment in endothelium NO availabil-
ity. NO pathway may be additionally inhibited indirectly by
endothelialmicroparticles(EMPs), small vesicularfragments
of the endothelial cell membrane released during activa-
tion or apoptosis [19]. EMPs possible can be induced by
indoxyl sulfate and p-cresyl sulfate (both classiﬁed as small
molecules), and, together with AGES and ADMA, are com-
pounds with the potential to induce vascular damage [24].
In addition, parathyroid hormone (PTH) is also recog-
n iz eda sam a j orur em ict o xin ,a lth oughitsin cr ea s edc on c en -
tration in CKD patients is merely attributable to enhanced
glandular secretion, rather than to decreased removal by the
kidneys. Excess PTH gives rise to an increase in intracellular
calcium, which results in functional disturbances in most or-
gan systems [25]. Later in the progression of vascular disease
development, vascular calciﬁcation is markedly higher in
CKD patients. Hyperphosphatemia is a driving force in the
pathogenesis of vascular calciﬁcation (VC) and secondary
hyperparathyroidism associated with renal failure. Because
secondary hyperparathyroidism is associated with morbidity
and mortality in patients with chronic kidney disease, sup-
pression of parathyroid hormone (PTH) and minimization
of associated derangements in mineral metabolism are car-
dinal therapeutic goals [26]. Indeed, Neves et al. [27]d e -
monstrated in an animal model of uremia that infusion
of synthetic PTH at a supraphysiologic rate contributed to
vascular calciﬁcation.
Recently, we demonstrated using in vitro and in vivo
models that exposure of endothelium to uremic plasma
results in time- and CKD-stage-dependent increased expres-
sions of monocyte chemoattractant protein-1 (MCP-1),
solublevascularadhesion molecule-1(sVCAM-1),andinter-
leukin-8, which suggest a link between vascular activation,
systemic inﬂammation, and uremic toxicity [28]. Further-
more, we investigate the eﬀect of a toxin called endotoxin
(ET) that may interfere in endothelial dysfunction and is
commonly observed in CKD patients. ET is constituted by a
lipopolysaccharide(LPS)complexpresentintheoutermem-
brane ofgram negative bacteria. In this groupof patients,the
sourcesofthesemoleculescouldbecontamination oftissues,
ﬂuids,or foreignbodiesand translocation from theintestinal
lumen related to an impaired intestinal barrier function.
There is increasing evidence that patients with CKD develop
signs of ﬂuid overload in the early phases of the disease,
and this may be a stimulus for inﬂammatory activation [29]
that may lead to accelerated CVD and rapid progression of
renal failure [30, 31]. One of the main epiphenomena of
endothelial dysfunction is the decline of eNOS. Patients in
CKD stage 5 have decreased NO production which in turns
causes an impaired endothelium-dependent vasodilatation.
Furthermore, decline production in NO also can lead to
elevated levels of ET and proinﬂammatory cytokines found
in uremia resulting in attenuated prothrombotic potential of
endothelial cells [32].
4.Genetic ContributioninCVDin
CKDPatients
Epigenetics is a new area dedicated to the study of the chan-
ges that occur in primary cell genome as a result of changesInternational Journal of Hypertension 3
in the conformation of DNA generated by the environment.
These may include cytosine methylation, histone modiﬁca-
tions, chromatin remodeling, and silencing RNA-dependent
[33]. Changes in DNA through methylation (addition of
methyl groups at carbon 5 of cytosine of CpG nucleotide
groups) have important regulatory role in pathological pro-
cesses and contribute to normal development and dif-
ferentiation of tissues. Epigenetic modiﬁcations are cru-
cial in several diseases such as cancer, atherosclerosis, and
autoimmune diseases [34], and recently some studies have
demonstrated that gene inactivation of estrogen receptor-
α has an important role in atherogenesis and aging of
the vascular system [3]. Previous studies have shown that
dyslipidemia, oxidative stress, hyperhomocysteinemia, and
inﬂammation may result in imbalance in DNA methylation,
so it can be suggested that the uremic environment may
also have a signiﬁcant eﬀect on the epigenome [33], as
demonstrated by Stenvinkel et al. in studies performed in
peripheral blood lymphocytes from hemodialysis patients,
where they found signs of DNA hypomethylation [34].
Homocysteine and uremic toxin and its precursor, S-
adenosylhomocysteine,areelevatedinuremia[35].Likewise,
recent studies have demonstrated in vitro that homocys-
teine causes methylation of estrogen receptor-α genes and
promoter ApoE gene (considered antiatherosclerotic) [36,
37].
Zaza et al. demonstrated in peripheral polymorphonu-
clear cells from CKD patients through genomic studies in-
volvingmorethan15,000candidategenesthatMIF,CXCL12,
and IL8RB genes were independentlyassociated with inﬂam-
mation, and CXCL12 and IL8RB genes were inversely cor-
related to C reactive protein (CRP) and highly expressed
in peritoneal dialysis patients and CKD, respectively [38].
The Stroma cell-derived factor 1 (SDF-1), also known as
CXCL12, expressed by CXCL12 gene is a CXC chemokine
[39]and exertsitsactivity bybinding itsreceptor,a Gprotein
called CXCR4 on the cell surface [40]. SDF-1 was originally
characterized by stimulating T lymphocytes, B lymphocytes,
and monocytes. However, it was discovered that his action
is restricted not only in immune and hematopoietic cells but
also in the central nervous system and endothelial cells [41],
developing important roles in pathophysiology processes
such as inﬂammation, angiogenesis, and wound healing.
Furthermore, SDF-1 is critical for growth, survival, and
metastatic spread of various tumor types [40]. Additionally,
it was suggested that SDF-1 plays a pivotal role in induced
stem cell mobilization, and targeted expression of SDF-1
after myocardial infarction was shown to result in increased
engraftment of bone-marrow-derived stem cells into in-
farcted myocardium [42]. In this context, Jie et al. showed
an increase of this cytokine in pre-dialysis patients samples
when compared with controls [43].
Despite the constant uremic state, diﬀerences like socio-
economic and cardiovascular risk and risk factors as hyper-
tension and diabetes in CKD patients are known, pointing
that additional factors should be involved, like genetic risk
factors [44]. It was demonstrated in biopsies from skele-
tal muscle from hemodialysis patients, genes that were
upregulated (GADD45A, BTG2, PDE4B,a n dCEBPD), and
ag e n e( TOB1) that was downregulated compared with con-
trols [45]. Also, recently, it was demonstrated in a 67,093
study population from 20 predominantly population-based
cohortswithintheCKDGenconsortium,anewsusceptibility
loci for reduced renal function. They identiﬁed 20 new
replicated loci associated with GFR and CKD. Of these, 13
arelikelytobeinvolvedinrenalfunctionandinsusceptibility
to CKD, whereas 7 are likely to be associated with creatinine
production or secretion, identifying common genetic vari-
ants in genes related to nephrogenesis (ALMS1,VEGFA, and,
potentially, DACH1), glomerular ﬁltration barrier formation
and podocyte function (DAB2, PARD3B, and VEGFA),
angiogenesis(VEGFA),solutetransport(SLC7A9,SLC34A1),
and metabolic functions of the kidney (PRKAG2and, poten-
tially, GCKR and LASS2)[ 44]. These recent technological
advances in discovering new disease susceptibility genes will
improve the understanding of important mechanisms for
renal development and CKD pathogenesis, contributing to
establish novel treatment strategies based on genomic infor-
mation related to kidney disease.
5.Conclusions
Beyond hypertension, novel mechanisms involved in the
vascular damage in CKD have been recently described. Par-
ticularly, the involvement of uremic toxins and epigenetics
on the uremia-related CVD emerge as important candidates
responsible for endothelial activation and increased CVD
risk, with potential impact on risk stratiﬁcation and devel-
opment of novel therapeutic options.
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